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Telomerase is a reverse transcriptase that maintains telomere length.[1] Telomerase activity
is suppressed in somatic cells such that telomere attrition triggers replicative senescence or
apop-tosis.[2] In cancer cells, telomerase is up-regulated or reactivated, effectively making
the cell immortal.[3] Previous studies have shown that telomerase activity positively
correlates with unfavorable cancer prognosis.[4] Since it was discovered that activation of
telomerase is a rate-limiting step in carcinogenesis, telomerase has gained much interest as a
drug target. Both screening and structure-based methods have been extensively employed to
identify small molecule leads that can selectively disrupt telomerase activity. Strategies
commonly used to target telomerase activity include but are not limited to targeting the
reverse transcriptase subunit of telomerase (BIBR1532 and nucleoside ananlogs),[5–7]
inhibiting hTERT phosphorylation using inhibitors of protein kinase C,[8] targeting the RNA
component of telomerase (peptide nucleic acids, antisense oligonucleotides -
GRN163L),[9, 10] stabilizing G-quaduplex structures,[11] and using T-oligos that mimic the
end of human telomeres to induce a DNA-damage response.[12] Nonetheless, with the
exception of GRN163L that has recently entered into Phase III clinical trials, attempts at
clinically targeting telomerase activity using classic small molecule derivatives have largely
been unsuccessful.
An alternative strategy is to target proteins involved in telomere protection and maintenance.
Telomeres are coated and maintained by a network of sequence-specific DNA-binding
factors that tightly control telomerase activity, including TRF1, TRF2, tankyrases, and
TIN2. In particular, TRF1 acts in cis at chromosome ends to repress telomere elongation by
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preventing telomerase from accessing the telomeres.[13] Increasing TRF1 levels will cause
telomere shortening followed by replicative senescence or apoptosis.[14] Previous studies
have shown that overexpression of TRF1 results in gradual telomere shortening,[13–15]
whereas overexpression of dominant-negative mutants leads to telomere elongation in
cells.[14, 16, 17]
A variety of factors contribute to telomere-bound TRF1 levels. Currently, two E3 ligases are
known to mediate the ubiquitination and degradation of TRF1. The RING H2 zinc finger
protein RLIM binds to a site adjacent to the myb domain of TRF1, and localizes to the
nucleus upon binding with TRF1.[18] Studies have shown that overexpression of RLIM
decreases the level of TRF1, and that shRNA knockdown of RLIM increases the level of
TRF1 leading to telomere shortening and impaired cell growth.[18] SCFFbx4, on the other
hand, binds to the TRFH domain of TRF1 via an atypical small GTPase domain and
localizes to the cytoplasm upon binding with its substrate.[19] Zeng et al. showed that TRF1
has a higher binding affinity to TIN2 than to Fbx4,[19] and crystal structures indicate that the
Fbx4-TRF1 binding interface overlaps with the TIN2-TRF1 interface, which may allow
TIN2 to sequester TRF1 from Fbx4 in vivo. Studies have also shown that nucleostemin (NS)
and guanine nucleotide binding protein-like 3 (GNL3L), GTP-binding proteins that shuttle
between the nucleolar-nuclear compartments, bind to TRF1.[20] GNL3L has been shown to
stabilize TRF1, whereas NS has been shown to enhance the degradation of TRF1.[21,22]
Despite the complexity involved in TRF1 regulation, blocking TRF1 ubiquitination should
theoretically lead to increased levels of TRF1, gradual shortening of telomeres, and
replicative senescence or apoptosis.
Fbx4 functions as the substrate specific adaptor subunit of SCFFbx4 that recognizes both
TRF1 and cyclin D1 as substrates.[23] The interaction between TRF1 and Fbx4 was initially
discovered from a two-hybrid screen.[24] It was later found that over-expression of Fbx4
reduces endogenous TRF1 levels and causes the telomeres to lengthen progressively.[23]
Inhibition of Fbx4 by RNA interference (RNAi), on the other hand, stabilizes TRF1 and
promotes telomere shortening, which ultimately impairs cell growth.[23] RNAi studies
demonstrated that knockdown expression of Fbx4 results in stabilization of TRF1 (19,24).
Furthermore, disabling the binding interaction between TRF1 and Fbx4 abrogates TRF1
ubiquitination both in vitro and in vivo.[19]
In this study, we directly targeted the E3 ligase (SCFFbx4) – substrate (TRF1) interface using
computationally enhanced peptide inhibitors derived from the TRF1TRFH-Fbx4G crystal
structure. The approach was based on the hypothesis that TRF1-binding peptides optimized
in silico will prevent ubiquitination - a critical step in regulating the levels of TRF1. TRF1
levels are controlled by sequential post translational modifications and subsequent
degradation. ADP-ribosylation of TRF1 by tankyrase 1 releases TRF1 from telomeres, and
ubiquitination of TRF1 is achieved through an enzymatic cascade, involving a series of
cooperative protein-protein interactions.[25] In principle, each step is susceptible to specific
inhibition. In particular, the specificity-conferring nature of E3 ligase-substrate interactions
makes them prime candidates as targets for cancer therapy. However, only a few inhibitors
that exploit E3 ligase-substrate interfaces are known up to this date - the Nutlins being the
most thoroughly characterized among them. In the case of Nutlins, a crystal structure
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determined by Pavletich et al. revealed a deep hydro-phobic pocket located at the interface
of MDM2 and p53,[26, 27] prior to conducting the small-molecule screen. Such well-defined
cavities have not been documented for RING domain E3s and their substrates, including and
Fbx4 and TRF1. In recent years, peptides that disrupt protein-protein interactions are
emerging as modulators of signaling pathways. For instance, both natural and unnatural
peptide inhibitors that disrupt the MDM2-p53 interaction were identified.[28–30] However, it
remains a challenge to use a rationally designed, short peptides that possess a high degree of
conformational freedom to target protein-protein interfaces.
The 2.4 Å resolution crystal structure determined by Zeng et al. reveals the molecular basis
by which Fbx4 recognizes TRF1.[19] In particular, the αD helix of Fbx4G reinforces the
formation of the TRF1TRFH-Fbx4G complex by contacting TRF1TRFH via extensive van der
Waals interactions. This short helix packs against a slightly indented hydrophobic area that
spans the surface of both molecules. Mutations made on both sides of the interface are
sufficient to abolish TRF1TRFH-Fbx4G binding in vitro and in vivo,[19] suggesting that it is
possible to target the TRF1TRFH-Fbx4G interface using peptides. London et al. examined
151 protein-protein structures as starting points for the derivation of high-affinity peptide
segments that could be extracted from one binding partner, and used as inhibitors against the
wild-type interaction.[31] Their results indicate that short linear segments contribute a
majority of the binding energy for more than 50% of the examined protein-protein
interactions. Evaluating the TRF1TRFH-Fbx4G interface shows the short helical segment of
Fbx4G comprising residues 339-348, contributes more than half of the total buried surface
area at the interface (689 Å2 of 1371 Å2 total), and buries numerous hydrophobic residues.
Hence, we believed that this segment is likely to provide a good starting point.
The short peptide does in fact act as an inhibitor of the wild-type interaction, with a
moderate IC50 of 205.9 μM obtained from in vitro ubiquitination assays. Fluorescence
polarization experi-ments show that the selected peptide binds to TRF1TRFH with a Kd of
41.8 μM (Table 1). While the initial peptide displays promising results, we sought to
enhance its inhibitory potency of the TRF1TRFH-Fbx4G interaction through rational peptide
design.
A structure-based design protocol [32, 33] using Rosetta [34] was empolyed to enhance the
affinity of a 9 residue linear segment (MPCFYLAHE - residues 339 to 347), that spans the
length of the αD helix of Fbx4G, to TRF1. Previous work found that protein-protein
interactions can be reliably enhanced by increasing the buried hydrophobic surface area at
the interface.[32] Two positions were identified as candidates for the introduction of larger
hydrophobic residues, C341I and A345F. Solubility was a concern when isolating the
segment from a larger globular protein. In addition, increasing the hydrophobicity of the
extracted peptide in an effort to enhance binding affinity can lead to a further decrease in
solubility. Thus, we replaced a solvent-exposed leucine residue with a lysine residue,
L344K, and added two hydrophilic residues, S349 and K350, to the C-terminus of the
peptide (Table 1). Finally, we sought to stabilize the short helical peptide by adding a C-
terminal capping motif. We anticipated that these affinity-enhancing measures will provide a
large contribution to the overall affinity of the peptide-TRF1 complex. In addition, we
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generated two alanine substitution variants (Designs 2 and 3) to further assess the
importance of the two key interface residues (F342 and F345).
To address the issues of peptide solubility, we performed analytical ultracentrifugation
(AUC). Examination of the AUC data shows that Designs 1, 2, and 3 do not self-associate,
and are monomers in solution (Figure S1). However, the data also suggests Designs 1 and 2
sample multiple conformations. To examine the biological activity of the peptide designs,
we reconstituted Fbx4-dependent TRF1 ubiquitination in vitro. Although phosphorylation is
not a prerequisite for ubiquitination [19], wild-type TRF1 was first phosphorylated using
cyclinB-Cdk1 in the presence of 33P-γ-ATP to allow quantitative detection. We then
incubated TRF1 with recombinant ubiquitin, E1, E2 (UbcH5a), and the SCFFbx4 complex.
Increasing amounts of peptide inhibitors were added to the reaction mixture, and the relative
effectiveness of the peptide inhibitors were determined by measuring the disruption of
polyubiquitination, from which the IC50 values were generated. The tested peptides showed
a range of inhibitory effects from none to more potent. The rationally optimized peptide
inhibitor (Design 1) shows enhanced inhibitory activity, with an IC50 that is decreased by
more than 6-fold (31.3 µM), showing robust inhibition of polyubiquitination compared to
the minimally sized wild-type peptide lacking the modifications (IC50 = 205.9 µM). Both
alanine substitution variants of the original design, Design 2 and 3, resulted in a loss of
inhibitory activity compared to Design 1 as seen by the IC50 values (270.6 μM and 95.8 μM,
respectively) obtained from the in vitro ubiquitination experiments. In contrast, control
peptides 1 and 2 showed little or no inhibitory activity. However, the variation in Hill
coefficients suggests that the mechanism of inhibition may be slightly different for each
peptide design (Figure 2C). In summary, although all of the peptides derived from the αD
helix of Fbx4 showed inhibition in the lower micromolar range, the inhibitory potency
varied, with IC50 values ranging from 31.3 to 270.6 µM.
We then tested our computationally enhanced peptide inhibitor (Design 1) and their alanine
substitution variants (Designs 2 and 3) via a fluorescence polarization binding assay to
directly determine their binding affinities to TRF1TRFH, and further assess the predicted
binding mode. Peptides were labeled with 7-hydroxycoumarin as the fluorophore. Holding
the peptide concentration at 0.1 µM, we added increasing concentrations of TRF1TRFH
protein (up to 80 µM), measured polarization values, and generated equilibrium binding
isotherms (Figure 4A). The dissociation constants (Kd) were determined to be 23.3 μM, 47.8
μM, 17.3 μM, and 41.8 μM for Design 1, Design 2, Design 3, and Wild-Type, respectively
(Table 1). The increase in binding affinities for the computationally enhanced peptides with
respect to wild-type was 1.8 to 2.4 fold - with the exception of Design 2, where a slight
decrease in affinity was seen. The affinity enhancement for Design 3 suggests that the first
phenylalanine residue of Design 1 contributes to binding. The role of the second
phenylalaine residue in Design 1 is less clear. The negative controls, by contrast, could not
be saturated within the same range of concentrations of TRF1TRFH, or even exhibited
nonspecific binding. The fluorescence polarization experiments show that, in general, the
designed peptides have lower Kd values compared to the control peptides, which is
consistent with their potency observed in the in vitro ubiquitination assays. These results
suggest that differences in binding affinities between peptides and TRF1TRFH largely
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account for the differences in the biological activities of the peptide inhibitors, although
there are rare exceptions to this correlation.
It is important to note that the peptide (Design 1), which exhibited the lowest IC50 value, did
not show the highest affinity for TRF1TRFH. An increase in binding affinity does not always
directly translate into more favorable biological activity. The fact that our binding data does
not completely correlate with our in vitro ubiquination results is puzzling at first glance, but
if we consider the muti-step and muti-component nature of the ubiquitination process, this
discrepancy might not be surprising. The ubiquitin proteasome system contains a number of
synergistic proteins that can potentially be influenced by distal binding events. Therefore,
each component of the ubiquitination cascade can, in theory, be targeted by the peptide
inhibitors: The inhibitors may be involoved in non-specific interactions at high micromolar
concentrations, as implied by the in vitro ubiquitination control experiments (Figure 2B).
Explicitly, the discrepancies between the IC50 values, obtained from the in vitro
ubiquitination experiments where multiple proteins are present, and the Kd values, with only
the target protein and inhibitor peptide present, suggest that non-specific and competing
interactions are taking place with additional protein components. In addition, the fact that
Design 3 results in decreased inhibition but tighter binding demonstrates that short peptides
can adopt a number of conformations, which differs considerably from the behavior of a
typical globular proteins. The difficulty in predicting and controlling such conformations
poses additional challenges in peptide inhibitor design.
To elucidate the mechanism of binding, we examined whether mutations of residues located
at the interface of TRF1TRFH could weaken or disrupt the peptide-TRF1TRFH interactions.
The crystal structure determined by Zeng et al. [19] shows that Leu115 and L120 of
TRF1TRFH, located at the interface, both directly interact with the αD helix of Fbx4. In fact,
these point mutations have been shown to disrupt the interaction of TRF1TRFH with Fbx4G
in both GST-pull-down and yeast two-hybrid assays.[19] Therefore, we speculated that
substituting these residues with a positively charged bulkier arginine residue via site directed
mutagenesis will abrogate binding activity between the peptide inhibitor and TRF1TRFH.
The TRF1TRFH mutants, L115R and L120R, were expressed, purified, and similar
fluorescence polarization assays were carried out. As speculated, the fluorescence
polarization studies revealed that the mutations impair the interaction between TRF1TRFH
and the peptides (Figure 3B and 3C). The combined site-directed mutagenesis and peptide-
binding experiments suggest that certain hydrophobic interactions between the peptides and
TRF1 are necessary for binding. The results of our assays also suggest that peptide-
TRF1TRFH binding occurs in a non-promiscuous manner, and that the inhibitors act via a
specific mechanism, in good agreement with the computational model.
The specificity of the design was further evaluated by assessing their effects on p27
ubiquitination. A recombinant assay system containing ubiquitin, E1, E2 (hCdc34), Cks1,
p27 phosphorylated by cyclin E-Cdk2, and the SCFSkp2 complex was used. The SCF
complex of this system is equivalent to SCFFbx4 except for the fact that Fbx4 is switched out
for Skp2, where Skp2 plays the critical role of specifically recognizing its substrate p27.
Skp2 and Fbx4 which both belong to the F-box family, share very limited homology.[35] Our
in vitro ubiquitination assays revealed that the computationally enhanced peptide inhibitor
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has no effect on the ubiquitination of p27 (Figure S3). Taken together, the biochemical and
biophysical data demonstrate that the computationally designed peptide inhibitors
specifically disrupt the TRF1TRFH-Fbx4G interaction.
With regards to specificity, the fact that Fbx4 recognizes both TRF1 and CyclinD1 makes
TRF1 a slightly less than ideal target from a clinical standpoint. Both substrates are involved
in the regulation of cell growth and proliferation. However, ubiquitination of cyclin D1
requires the presence of the adaptor αB-crystallin and phosphorylation at Thr286.[36]
Ubiquitination of TRF1, on the other hand, does not require an adaptor protein, nor is
phosphorylation of TRF1 necessary for its association with Fbx4. This implies that there
may be some structural differences between the TRF-Fbx4 interaction and the Fbx4-αB-
crystallin-cyclin D1 interaction. In addition, studies have shown that TIN2 and Fbx4 have
overlapping TRF1-binding interfaces.[19] This suggests that TIN2 may block TRF1
recognition by Fbx4, thereby preventing SCFFbx4 mediated ubiquitination and degradation.
Recently, it has been shown that telomerase-negative cancer cells are capable of maintaining
their telomeres by a mechanism known as alternative lengthening of telomeres (ALT).
Evidence also suggests that TRF1 may have a role outside of telomere maintenance,[20]
which may lead to further complications. These factors are likely to influence the
practicality of targeting TRF1 degradation from a clinical standpoint, but the efficacy of the
approach remains to be determined as was for the case of the FDA approved proteasome
inhibitor bortezomib.[37] It is also important to note that, F142, located in the TRFH domain
of TRF1, serves as a docking site for the FxLxP motif-containing proteins TIN2, PINX1,
ATM, BLM, and DNA-PKcs, but does not play a significant role in the binding interaction
between TRF1TRFH and Fbx4, which lacks the FxLxP motif. This mechanistic difference in
binding may potentially be exploited in enhancing inhibitor specificity.
In summary, our studies have validated the feasibility of designing peptides that selectively
disrupt E3 ligase-substrate interactions, in the absence of large binding pockets, by
rationally targeting specific regions of interface. We have also demonstrat-ed the
applicability of our in silico Rosetta protocol in increasing peptide-protein affinities. Such
inhibitors have the potential to be used as drug precursors that can aid the mechanistic
studies of disease related protein-protein interactions.
Experimental Section
Inhibitory peptide design
The backbone coordinates for sequence positions 339 to 347 (MPCFYLAHE) were isolated
from F-box only protein 4 (Fbx4G) in the TRF1TRFH-Fbx4G complex (PDB code 3L82) for
inhibitor peptide design 1. The helical region was extended in the C-terminal direction in an
effort to stabilize the bound peptide conformation and thus limit the configurational entropy
loss. The helix extension was achieved by aligning an alpha helix from the TRF1TRFH
binding partner with the isolated Fbx4G helix. As a result, four additional positions were
added to the helix, although the three C-terminal positions do not make contact with the
target protein, TRF1TRFH, in the model structure. The first four N-H groups and the last four
C=O groups of an alpha helix lack intrahelical hydrogen bond partners, potentially
destabilizing the helical secondary structure. N-terminal C-terminal helix-capping motifs
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have been identified in both proteins and peptides, and are thought to provide a mechanism
to stabilize the helical secondary structure.[38] A glycine-threonine-glycine motif was
appended to the C-terminus of the inhibitor peptide designs to ideally act as a C-terminal
helix cap. Sequence positions that had been buried in the globular Fbx4 structure became
solvent exposed positions in the inhibitor peptides and thus theses positions were
redesigned, allowing only polar or charged amino acids. Previous work had shown that
increasing buried hydrophobic surface area could be an effective approach to enhance
protein-protein binding affinity [32]. Thus, positions that were buried or peripheral to the
interface between the inhibitor peptide and the target protein were redesigned in an effort to
increase the buried hydrophobic surface area. Three positions from the precursor Fbx4
sequence were retained. The N-terminal position, P340, was not altered to conserve the phi-
psi dihedral angles that may play a role in the interaction between the proline residue and the
target protein TRF1. The position M339 was also retained. H346 was retained due to the
hydrogen bonding with Y124 from the target protein. Sequence design and structural
optimization was done with the molecular modeling program Rosetta.[34] A version of the
Rosetta energy function with a dampened Lennard-Jones repulsion potential was used.[39]
Peptide synthesis
Solid-phase synthesis of peptides was carried out using Fmoc protected amino acids and
Rink amide SS resin (200-400 mesh, Nova Biochem) on a CEM Liberty automated
microwave peptide synthesizer (CEM Corporation). Dried resin was swelled in
dichloromethane (30 min). The Fmoc group was removed using a solution of 20%
piperidine in dimethylformamide (DMF). The deprotected resin was then suspended in a
solution containing Fmoc-protected amino acid (5 eq.), HATU (5 eq.), DIPEA (10 eq.), and
DMF (4 mL). Couplings were performed in duplicates. Deprotection and coupling were
repeated until all residues were incorporated according to the peptide design. The
fluorophore-labeled peptides were prepared on solid phase using 7- hydroxycoumarin-3-
carboxylic acid (AnaSpec, Inc., CA) following the coupling conditions described above. The
resulting peptides, with an amidated C-terminus and a free amino N-terminus were cleaved
from resin and side-chain protecting groups were removed using a mixture of trifluoroacetic
acid/water/1,2-ethanedithiol/triisopropylsilane (94:2.5:2.5:1 v/v) at room temperature (2h).
The crude peptides were collected by precipitation with cold diethyl either (SigmaAldrich,
MO). The peptides were purified using Agilent 1200 series semipreparative reverse phase
high-performance liquid chromatrography system (Santa Clara, CA) with an Agilent Zorbax
300 SB-C8 column using a linear gradient buffer A (water/acetonitrile 9:1 v/v) and buffer B
(acetonitrile), followed by lyophilization to dryness. The peptides were characterized using
Matrix-assisted laser desorption/ionization time-of-flight mass spectrometer (MALDI-TOF)
on a Voyager DE-STR Biospectrometry Workstation (PerSeptive Biosystems, CA).
Protein expression and purification
For the fluorescence polarization assays, TRF1TRFH (residues 58–268) fused to a Sumo
protein and N terminal His6 tag was expressed in E. Coli.[19] After a 6 hr induction using
IPTG (0.1 mM) at 25°C, the cells were harvested by centrifugation. The harvested cell
pellets were resuspended in lysis buffer (50 mM NaH2PO4, pH 8.0, 300 mM NaCl, 10 mM
imidazole, 1 mM PMSF, 1mM DTT) and lysed by sonication. The lysates were cleared
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using ultracentrifugation and the resulting supernatant was incubated with Ni-NTA agarose
beads (1 hr) at 4°C. The beads were then washed with 20 mM imidazole and before eluting
TRF1TRFH with 250 mM imidazole. The resulting TRF1TRFH was further purified using a
HiLoad Superdex 200 column (GE Healthcare) after cleaving off the His6-Sumo tag using
the Ulp1 protease. For the in vitro ubiquitination assays, the TRF1 deletion mutant
TRF1ΔMyb was expressed in E. coli and purified using the same procedure as for
TRF1TRFH, with the addition of two affinity purification steps using Mono-Q and Mono-S
ion exchange columns (GE Healthcare). GST-tagged Fbx4 with two deletions (residues 1-54
and 150-170) was coexpressed with truncated Skp1[40] was also expressed in E. coli as a
dicistronic message for 6 hrs at 25°C using IPTG (0.1 mM). The harvested cell pellets were
resuspended in NETN buffer (Tris-base, pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.5 % NP40,
1 mM DTT). After lysing the cells by sonication the cell debris was removed by
ultraceltrifugation, and the supernatant was mixed with glutathione sepharose beads
(QIAGEN) for 1 hr at 4°C before elution with glutathione (20 mM). The complex was then
further purified by gel filtration chromatography using the HiLoad Superdex 200 column.
E1, UbcH5a (E2), Cul1-Rbx1, and Skp1-Skp2 were expressed and purified as
described.[41, 42]
Fluorescence polarization assay
Fluorescence polarization experiments were conducted on a Fluorolog-3 spectrofluorometer
(Horiba Jobin Yvon, Inc). Coumarin-labeled peptides were dissolved into buffer (200 mM
NaCl, 10mM DTT, 25 mM Tris pH 8.0). TRF1TRFH protein was titrated into 100 nM
peptide solutions (up to 250 µM). An excitation wavelength of 302 nm and an emission
wavelength of 448 nm were used. Spectra were measured using 7.0 nm slit widths at 25°C.
Curve fitting and regression analysis performed using Sigma Plot 10.0 (SPSS Inc.). Data
were fit to a quadratic single site binding equation Eq. (1), which was incorporated into Eq.
(2) to account for the observed polarization:
(1)
(2)
where [A:B] is the concentration of coumarin labeled peptide and TRF1TRFH protein
complex formed, [At] is the total concentration of coumarin-labeled peptide, [Bt] is the
concentration of TRF1TRFH protein, Pmax is the maximum polarization observed when all
coumarin-labeled peptide is bound to TRF1TRFH protein, and Pobs is the measured
polarization at a given concentration of TRF1TRFH protein. The obtained fitted parameters
were for Kd, Pmax, and Po.
In vitro TRF1 ubiquitination assay
[γ-33P]-labeled TRF1 proteins (4 mM) were generated by incubating the TRF1 with GST-
cyclin B/Cdk1 (0.1 mM) in a buffer composed of Tris (50 mM, pH 8.0), MgCl2 (10 mM),
Lee et al. Page 8
Chembiochem. Author manuscript; available in PMC 2014 May 20.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
ATP (10 mM), and [γ-33P] ATP (2 µCi) for 1 hr. GST-cyclinB/Cdk1 was removed from the
phosphorylated TRF1 by means of glutathione affinity chromatography. Ubiquitination
assays were performed by incubating the phosphorylated TRF1 with E1 (0.5 mM), UbcH5a
(E2; 5 mM), SCFFbx4 complex (E3; 1 mM), ubiquitin (5 mM), methylated ubiquitin (100
mM), and 20X energy regeneration system (1 µL; 10 mM ATP, 20 mM HEPES [pH 7.4], 10
mM MgOAc, 300 mM creatine phosphate, and 0.5 mg/ml creatine phosphokinase) in a final
volume of 15 ul. The reactions mixtures were incubated at 30°C for 2.5 hrs, and terminated
by boiling after addition of Laemmli sample. The proteins were separated by SDS-PAGE
and the resulting gels were dried prior to phosphoimaging analysis.
CD Spectroscopy
Spectra were recorded on a Chirascan™ - plus CD Spectrometer (Applied Photophysics)
using a protein con-centration of 12 µM (0.1 cm path length). Protein concentrations were
determined by UV absorbance at 280 nm. Sixteen scans from 195 to 260 nm were averaged.
All spectra were measured at 25°C Results were recorded in millidegrees.
Analytical Ultracentrifugation
The hydrodynamic properties of peptides Design 1, Design 2 and Design 3 were analyzed by
analytical ultracentrifugation using sedimentation velocity. The experiments were performed
in a Beckman XL-I analytical ultracentrifuge (Beckman Coulter, CA) at 25°C. S20,w and the
frictional ratio (f/f0) was determined using Ultrascan III software using 2-D spectrum
analysis and genetic algorithm. [43]
In vitro p27 ubiquitination assay
[γ-33P]-labeled p27 proteins were generated by incubating the p27 with GST-cyclin E/Cdk2
(0.1 mM) in a buffer composed of Tris (50 mM, pH 8.0), MgCl2 (10 mM), ATP (10 mM),
and [γ-33P] ATP (2 µCi) for 1 hr. The ubiquitination reaction was carried out by incubating
the phosphorylated [γ-33P]-labeled p27 with E1 (0.5 mM), Cdc34 (E2; 5 mM), SCFSkp2
complex (E3; 1 mM), Cks1 (1 mM), ubiquitin (5 mM), methylated ubiquitin (100 mM), and
20X energy regeneration system (1 µL) for 2 hrs at 30°C. The proteins were analyzed by
SDS-PAGE and phosphoimaging.
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Figure 1.
Optimizing the anti-TRF1 peptide inhibitor. A) The peptide segment selected from the Fbx4
structure, shown bound to the TRF1 protein target based on the TRF1-Fbx4 crystal
structure.[19] B) Model of the rationally optimized peptide inhibitor. Both the original
inhibitor peptide and the rationally optimized inhibitor are shown with the same binding
mode as the peptide segment (residues 339-348) cut from the FBX4 protein. The peptides
are shown in cartoon representation with side chains located at key position of the interface
shown and labeled. The target protein, TRF1, is shown in surface representation.
Lee et al. Page 13
Chembiochem. Author manuscript; available in PMC 2014 May 20.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Lee et al. Page 14
Chembiochem. Author manuscript; available in PMC 2014 May 20.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2.
Peptides inhibit polyubiquitination in vitro. A) Inhibition profiles of computationally
enhanced peptide inhibitors. B) Inhibition profiles of control peptides. C) Normalized IC50
curves that represent the potency of the peptide designs. ImageJ was used to quantify the
disruption of polyubiquitination. Measurements represent the mean ± standard deviation
from three replicates.
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Figure 3.
WT and designed peptides bind to TRF1TRFH, but not to TRF1TRFHL115R or
TRF1TRFHL120R. A) Fluorescence polarization confirms that the WT and designed peptides
bind to TRF1TRFH. B) Mutation of Leu115 to arginine abrogates peptide protein complex
formation. C) Mutation of Leu120 to arginine abrogates peptide protein complex formation.
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Table 1
Experimental characterization of peptides
Peptide Sequence IC50(µM) KD(µM)
Wild-Type MPCFYLAHEL 205.9 41.8 ± 2.2
Design 1 MPIFWKFHRMSKMGTG 31.3 23.3 ± 12.8
Design 2 MPIAWKFHRMSKMGTG 270.6 47.8 ± 1.8
Design 3 MPIFWKAHRMSKMGTG 95.8 17.3 ± 4.9
Control 1 SMTWRGKPAHMIFGKM >550 >250
Control 2 KKMDVCGGLSD >4000 >10000
IC50 values were determined from the in vitro ubiquitination assays. Experiments were performed in triplicates. Data are expressed as mean ±
standard deviation for peptide-TRF1TRFH complex KD values.
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